Small cell lung cancer accounts for roughly 14% of all lung cancers and is characterized by rapid progression, early distant metastasis and poor prognosis. Only a minority of patients presents with early stage disease upon initial diagnosis where surgical resection may be discussed. In addition, various treatment modalities demonstrate effectiveness including chemotherapy and radiotherapy. However, although most patients respond to platinum doublet chemotherapy, virtually all patients with metastatic disease eventually develop tumor progression for which there are limited treatment options. Novel therapeutic approaches such as immune checkpoint inhibitors or the antibody drug conjugate rovalpituzumab tesirine show promising results in early clinical trials and might broaden our treatment options in the future.
«
Small cell lung cancer accounts for roughly 14% of all lung cancers and is characterized by rapid progression, early distant metastasis and poor prognosis. Only a minority of patients presents with early stage disease upon initial diagnosis where surgical resection may be discussed. In addition, various treatment modalities demonstrate effectiveness including chemotherapy and radiotherapy. However, although most patients respond to platinum doublet chemotherapy, virtually all patients with metas...
»